Browse
Browse
Home
People
Organizations
Research
Events
Capability Map
CA 180-372, AALL1122 A Phase 2, Multi-Center, Historically Controlled Study of Dasatinib added to Standard Chemotherapy for Relapsed/Refractory Ph+ALL
Grant
Overview
Affiliation
Overview
Awarded By
CHILDREN'S HOSPITAL (PHILADELPHIA)
Total Award Amount
0.00
Direct Costs
0.00
Sponsor Award Id
Affiliation
Contributor
Matthew Kutny M.D.
Principal Investigator